Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Pisansky

Showing results (131-140 of 135) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 135 results.
JAMA Oncology|November 20, 2025
Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-AnalysisNicholas G Zaorsky, Yilun Sun, Abdenour Nabid, et al.
European Urology|May 14, 2021
Patterns of Clinical Progression in Radiorecurrent High-risk Prostate CancerRebecca G Philipson, Tahmineh Romero, Jessica K Wong, et al.
JAMA Oncology|January 20, 2022
Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 CohortsAmar U Kishan, Alison Steigler, James W Denham, et al.
JAMA Network Open|July 1, 2021
Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic FeaturesAmar U Kishan, R Jeffrey Karnes, Tahmineh Romero, et al.
JAMA Network Open|December 13, 2021
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate CancerMichael Xiang, Ting Martin Ma, Ricky Savjani, et al.
Pageof 14

Showing results (131-140 of 135) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 135 results.
JAMA Oncology|November 20, 2025
Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-AnalysisNicholas G Zaorsky, Yilun Sun, Abdenour Nabid, et al.
European Urology|May 14, 2021
Patterns of Clinical Progression in Radiorecurrent High-risk Prostate CancerRebecca G Philipson, Tahmineh Romero, Jessica K Wong, et al.
JAMA Oncology|January 20, 2022
Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 CohortsAmar U Kishan, Alison Steigler, James W Denham, et al.
JAMA Network Open|July 1, 2021
Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic FeaturesAmar U Kishan, R Jeffrey Karnes, Tahmineh Romero, et al.
JAMA Network Open|December 13, 2021
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate CancerMichael Xiang, Ting Martin Ma, Ricky Savjani, et al.
Pageof 14